(Q42693621)

4 November 2017

Up to five years experience with 11 mucopolysaccharidosis type VI patients (English)

1 reference

4 November 2017

Marion M M G Brands

1

1 reference

4 November 2017

Esmee Oussoren

2

1 reference

4 November 2017

George J G Ruijter

3

1 reference

4 November 2017

Audrey A M Vollebregt

4

1 reference

4 November 2017

Hannerieke M P van den Hout

5

1 reference

4 November 2017

Koen F M Joosten

6

1 reference

4 November 2017

Wim C J Hop

7

1 reference

4 November 2017

Iris Plug

8

1 reference

4 November 2017

Ans T van der Ploeg

9

1 reference

4 November 2017

4 March 2013

1 reference

Molecular Genetics and Metabolism

4 November 2017

1 reference

4 November 2017

109

1 reference

4 November 2017

1

1 reference

4 November 2017

70-76

1 reference

The frequency of lysosomal storage diseases in The Netherlands.

4 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Mucopolysaccharidosis VI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Management guidelines for mucopolysaccharidosis VI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, o

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Left ventricular mass in 169 healthy children and young adults assessed by three-dimensional echocardiography.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Measuring health-related quality of life in children: the development of the TACQOL parent form

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Development and psychometric evaluation of the TAPQOL: a health-related quality of life instrument for 1-5-year-old children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-ac

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Erratum to: Enzyme replacement therapy for mucopolysaccharidosis VI—experience in Taiwan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Enzyme-replacement therapy in mucopolysaccharidosis I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Enzyme replacement treatment in type 1 and type 3 Gaucher's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Mucopolysaccharidosis VI: the Italian experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Bone, joint and tooth development in mucopolysaccharidoses: relevance to therapeutic options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Orthopaedic aspects of mucopolysaccharidoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Sleep abnormalities in untreated patients with mucopolysaccharidosis type VI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Disordered breathing during sleep in patients with mucopolysaccharidoses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Polysomnographic characteristics in patients with mucopolysaccharidoses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Heart valve macro- and microstructure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Hunter disease before and during enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Otorhinolaryngological manifestations of the mucopolysaccharidoses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Auditory characteristics and therapeutic effects of enzyme replacement in mouse model of the mucopolysaccharidosis (MPS) II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Inner ear pathology in the mucopolysaccharidosis VII mouse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Predicting health-related quality of life of parents of children with inherited metabolic diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.02.013

10.1016/J.YMGME.2013.02.013

7 January 2021

Identifiers

DOI

1 reference

4 November 2017

1 reference